X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
oncology (17) 17
index medicus (15) 15
humans (14) 14
carcinoma, non-small-cell lung - drug therapy (12) 12
chemotherapy (12) 12
lung neoplasms - drug therapy (12) 12
immunotherapy (10) 10
lung cancer (10) 10
nsclc (9) 9
female (8) 8
male (8) 8
open-label (8) 8
treatment outcome (8) 8
cancer (7) 7
lung neoplasms - pathology (7) 7
nivolumab (7) 7
carcinoma, non-small-cell lung - pathology (6) 6
care and treatment (6) 6
docetaxel (6) 6
lung neoplasms - mortality (6) 6
multicenter (6) 6
respiratory system (6) 6
antineoplastic combined chemotherapy protocols - therapeutic use (5) 5
bevacizumab (5) 5
carcinoma, non-small-cell lung - mortality (5) 5
lung cancer, non-small cell (5) 5
metastasis (5) 5
patients (5) 5
safety (5) 5
survival (5) 5
tumors (5) 5
adult (4) 4
aged (4) 4
aged, 80 and over (4) 4
antibodies, monoclonal, humanized - administration & dosage (4) 4
atezolizumab (4) 4
clinical trials (4) 4
medical prognosis (4) 4
middle aged (4) 4
neoplasm staging (4) 4
non-small cell lung cancer (4) 4
survival rate (4) 4
therapy (4) 4
antibodies, monoclonal - administration & dosage (3) 3
antibody mpdl3280a (3) 3
antineoplastic combined chemotherapy protocols - administration & dosage (3) 3
biomarkers (3) 3
cancer therapies (3) 3
carboplatin (3) 3
cisplatin - administration & dosage (3) 3
clinical activity (3) 3
disease-free survival (3) 3
follow-up studies (3) 3
ligands (3) 3
medicine, general & internal (3) 3
non-small cell lung carcinoma (3) 3
pd-l1 (3) 3
pd-l1 protein (3) 3
phase-iii (3) 3
prognosis (3) 3
solid tumors (3) 3
1st-line treatment (2) 2
abridged index medicus (2) 2
analysis (2) 2
anti-angiogenic treatment (2) 2
antibodies, monoclonal, humanized - adverse effects (2) 2
antibodies, monoclonal, humanized - therapeutic use (2) 2
antimitotic agents (2) 2
antineoplastic agents (2) 2
antineoplastic agents - administration & dosage (2) 2
antineoplastic agents, immunological - administration & dosage (2) 2
antineoplastic agents, immunological - adverse effects (2) 2
antineoplastic agents, immunological - therapeutic use (2) 2
antineoplastic combined chemotherapy protocols - adverse effects (2) 2
biotechnology & applied microbiology (2) 2
carboplatin - administration & dosage (2) 2
carcinoma, non-small-cell lung - diagnosis (2) 2
cell lung-cancer (2) 2
cell survival (2) 2
cisplatin (2) 2
combination therapy (2) 2
cytotoxic therapy (2) 2
dose escalation (2) 2
double-blind (2) 2
drug administration schedule (2) 2
germany - epidemiology (2) 2
glutamates - administration & dosage (2) 2
guanine - administration & dosage (2) 2
guanine - analogs & derivatives (2) 2
guidelines (2) 2
humanities (2) 2
immune checkpoint (2) 2
immune checkpoint inhibitor (2) 2
immune checkpoint inhibitors (2) 2
internal medicine (2) 2
lung carcinoma (2) 2
lung neoplasms - diagnosis (2) 2
medical and health sciences (2) 2
medical colleges (2) 2
medicin (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2016, Volume 387, Issue 10030, pp. 1837 - 1846
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 389, Issue 10066, pp. 255 - 265
Journal Article
Der Onkologe, ISSN 0947-8965, 12/2018, Volume 24, Issue 12, pp. 1003 - 1008
Die Behandlung des metastasierten nichtkleinzelligen Lungenkarzinoms (NSCLC) ohne behandelbare Treibermutation hat sich in den vergangenen Jahren insbesondere... 
Chemotherapie | Chemotherapy | Medicine & Public Health | Sequential therapy | Immuncheckpointinhibitoren | Oncology | Sequenztherapie | Immune checkpoint inhibitors | NSCLC Stadium IV | Kombinationstherapie | Combination therapy | NSCLC stage IV
Journal Article
Onkologe, ISSN 0947-8965, 12/2018, Volume 24, Issue 12, pp. 1003 - 1008
Journal Article
Der Onkologe, ISSN 0947-8965, 12/2018, Volume 24, Issue 12
Hintergrund Eine selektive Literaturrecherche der Datenbank Pubmed wurde durchgefuhrt. Suchbegriffe: NSCLC stage IV, checkpointinhibitors, chemotherapy. The... 
Care and treatment | Chemotherapy | Metastasis | Lung cancer, Non-small cell | Cancer
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 08/2013, Volume 31, Issue 24, pp. 3004 - U109
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 07/2018, Volume 24, Issue 14, pp. 3292 - 3298
Purpose: Standard endpoints often poorly predict overall survival (OS) with immunotherapies. We investigated the predictive performance of model-based tumor... 
CRITERIA | MULTICENTER | PEMBROLIZUMAB | SOLID TUMORS | ONCOLOGY | GUIDELINES | SIZE | IMMUNE-RELATED RESPONSE | OPEN-LABEL | RANDOMIZED CONTROLLED-TRIAL | DOCETAXEL | Models, Theoretical | Antibodies, Monoclonal, Humanized - adverse effects | Antineoplastic Agents, Immunological - administration & dosage | Lung Neoplasms - drug therapy | Antibodies, Monoclonal, Humanized - therapeutic use | Prognosis | Lung Neoplasms - mortality | Humans | Proportional Hazards Models | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Treatment Outcome | Carcinoma, Non-Small-Cell Lung - diagnosis | Tumor Burden | Molecular Targeted Therapy | Carcinoma, Non-Small-Cell Lung - mortality | Antineoplastic Agents, Immunological - adverse effects | Algorithms | Antibodies, Monoclonal, Humanized - administration & dosage | B7-H1 Antigen - antagonists & inhibitors | Antineoplastic Agents, Immunological - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Lung Neoplasms - diagnosis | Neoplasm Staging | Medical research | Subpopulations | Cell survival | Growth rate | Lung cancer | Clinical trials | Performance prediction | Shrinkage | Patients | Survival | Metastases | Chemotherapy | Immunotherapy | Medical prognosis | PD-L1 protein | Poplar | Cutoffs | Mathematical models | Kinetics | Cancer | Tumors
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2017, Volume 35, Issue 15_suppl, pp. e14517 - e14517
Journal Article
Deutsches Arzteblatt International, ISSN 1866-0452, 10/2013, Volume 110, Issue 43, pp. 719 - 724
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 01/2019, Volume 25, Issue 1, pp. 64 - 72
Purpose: HER2-targeted therapy is not standard of care for HER2-positive non-small cell lung cancer (NSCLC). This phase II study investigated efficacy and... 
TARGETED THERAPY | MUTANT | OVEREXPRESSION | PHASE-II TRIAL | AMPLIFICATION | SOLID TUMORS | ONCOLOGY | ACQUIRED-RESISTANCE | COMBINATION | HER2 MUTATION | EXPRESSION
Journal Article
Journal of Geriatric Oncology, ISSN 1879-4068, 05/2019, Volume 10, Issue 3, pp. 405 - 410
Lung cancer is the leading cause of cancer death worldwide. Older patients represent approximately half of the patient population and optimal management of... 
Aged patients | Care and treatment | Lung cancer | Methods | Cancer
Journal Article